3 news items
Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GRTS
9 May 24
2 data we recently shared are very promising as they suggest that GRANITE is potentially driving benefit in metastatic CRC patients and that our
What's Going On With Small Cap Cancer Vaccine Focused Gritstone Bio Stock On Tuesday?
GRTS
2 Apr 24
).
The study is designed to quantify the clinical benefit of maintenance therapy with GRANITE (GRT-C901/GRT-R902) in combination with immune
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
GRTS
1 Apr 24
). The randomized, controlled, open-label study is designed to quantify the clinical benefit of maintenance therapy with GRANITE (GRT-C901/GRT-R902
- Prev
- 1
- Next